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Objective: We developed a wallet-sized learning 
memory decision support system that helps patients 
with insulin-dependent diabetes mellitus adjust their 
insulin dosages. Research Design and Methods: To 
determine the efficacy of the support System, we 
designed a randomized clinical trial with patients 
participating in a program in a diabetes education 
center. Patients were assigned to two groups of 21 
patients each. All patients performed self-monitoring of 
blood glucose (SMBG) and were treated with multiple 
daily injections of insulin. Each of the patients was 
examined over a 32-day period. The basic educat :<nal 
program, i.e., practical advice in SMBG, diet, anc< 
exercise under homelike conditions, was indenti :cl in 
both groups. The only difference was that the fini 
group used the Computer for adjusting the insulin dose, 
whereas the second group received recommendadions 
from the education team. Results: The baseline H b A , 
levels (9.8 ± 1.6 vs. 9.9 ± 1.6%) of both groups < cd not 
differ significantly. Mean blood glucose over the ist 2 
wk of the study was higher (P < 0.01) in the secccid 
group (8.4 ± 1.4 vs. 9.2 ± 2.0 mM); the frequenctes of 
hypoglycemic episodes were not different (1.7 vs. 2.3%). 
Conclusions: Metabolie control and safety were 
comparable in both groups. Thus, patients may t: nefit 
from such a System at home where no support b* 
diabetes educators is available. Diabetes Care 14::75-80, 
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V arious sets of computerized algorithms (1-9) have been applied as therapeutic guidelines in the self-monitoring of blood glucose (SMBG; 10) in insulin-dependent diabetes mellitus (IDDM). 
Essentially, these algorithms intend to imitate the deci-
sion-making process of experienced diabetes educators. 
However, it seems that a considerable analytic effort, 
by means of the control theory (11,12) and mathemat-
ical modeling (13), is necessary to come close to the 
quality of human empirical decision making. 
In this study, we compared two groups of patients 
participating in an educational program for intensified 
insulin therapy in a diabetes education center. Basically, 
the program was identical in both groups. However, the 
patients received different decision support in adjusting 
their insulin dose. The personal explanations by an ed-
ucation team in one group were substituted by the use 
of a decision-support System called l e a r n i n g m e m o r y in 
the other. We hypothesized that metabolic control and 
safety would be comparable in both programs. 
RESEARCH DESIGN AND METHODS 
The input variables included the actual blood glucose, 
observed hypoglycemic episodes, estimated carbohy-
drate content, physical activity (score 0-5), and time of 
day and date taken from a hardware clock. The Output 
variables were the basal insulin dose (NPH injection) 
and the regulär insulin dose (regulär injection), which 
were recommended by the System. 
The coneept of the System is based on algorithms de-
signed to control the blood glucose in a near-normogly-
cemic ränge (see Appendix 1) and on a Statistical 
DIABETES CARE, VOL. 14, NO. 10, OCTOBER 1991 875 
DECISION SUPPORT SYSTEM FOR INSULIN DOSAGE 
glucose-insulin model (see Appendix 2). The model de-
termines insulin requirements for extra carbohydrates 
and physical activity in the individual patient. The ap-
plied control algorithms were derived from Skyler et al.'s 
algorithms (14,15). For the design of a control System, 
these algorithms have been modified according to the 
principles of engineering Optimum control theory 
(11,12). The complete sets of algorithms have been 
tested in >10,000 simulated situations with a metabolic 
Simulator before testing them in patients (17). 
Data input and Output were based on a planning-
learning concept. Each of the four intervals (morning, 
afternoon, evening, night) consisted of a planning phase 
in the beginning and a learning phase at the end. In the 
planning phase, actual blood glucose, planned carbo-
hydrate intake, and planned physical exercise for the 
next 4 - 6 h were estimated prospectively and entered 
into the learning memory System. In the learning phase 
at the end of the interval, the patient entered the re-
sulting blood glucose. The patient may have improved 
the system's recommendations by identifying implausi-
ble values (e.g., if the resulting blood glucose has been 
influenced by factors like sauna or alcohol). Implausible 
values can be excluded from learning. Based on the data 
recorded during planning and learning phases, the Sys-
tem addressed the following questions: 1) How should 
the insulin dose be adjusted to keep blood glucose in a 
near-normoglycemic target ränge? and 2) Are insulin 
Supplements necessary in this individual to compensate 
for the effect of carbohydrates and physical activity? The 
learning memory System condenses the Information of 
all recorded data and recommends an insulin dose ränge 
(e.g., regulär 7-9 U) in the subsequent planning phase. 
The final decision (e.g., regulär 7 U) is left to the patient. 
We designed a hardware prototype of the learning 
memory system especially for diabetes management 
(20). Technical data consisted of 128 kbytes R O M , 128 
kbytes R A M , a two-line display, three keys (increment, 
decrement, return) for simple ergonomic handling, real-
time hardware clock, and data interface RS 232. 
TABLE 1 
Patient criteria 
Selection 
Insulin-dependent diabetes mellitus (clinical Symptoms and fasting 
C-peptide <0.17 nM) 
Age >18 and <60 yr at randomization 
Exclusion 
Acute illness 
Chronic diseases that complicate diabetes treatment 
History of coronary heart disease 
Creatinine >130 |JLM 
Self-monitoring of blood glucose impossible (vision or psychologi-
cal problems) 
Hemoglobinopathy or hemolytic anemia 
Endocrine disorders other than corrected primary hypothyroidism 
or uncomplicated menstrual disorders 
Willful removal of the microchip from device 
TABLE 2 
Characteristics of patients at randomization 
Experimental Control 
Patients 21 21 
M/F 11/10 8/13 
Conventional treatment/multiple 
daily injections 5/16 6/15 
Age at onset of diabetes (yr) 20.3 ± 9.9 20.7 ± 1 1 . 6 
Age (yr) 31.9 ± 9.1 34.9 ± 10.9 
Creatinine (JAM) 85.2 ± 9.2 82.0 ± 9.2 
Body mass index (kg/m2) 23.7 ± 3.9 22.7 ± 2.1 
Insulin dose/body weight (U/kg) 0.63 ± 0.14 0.65 ± 0.13 
Baseline HbA, (%) 9.8 ± 1.6 9.9 ± 1.6 
Values are means ± SD. 
The study population consisted of patients with I D D M 
from the Helbachtal Diabetes Education Centre (21). 
The study was performed in accordance with the prin-
ciples of the Declaration of Helsinki. Each patient gave 
his written informed consent (22). 
Before starting education in the diabetes center, pa-
tients were investigated according to selection criteria 
(Table 1). Patients without exclusion criteria were ran-
domly assigned to an experimental or control group (Ta-
ble 1). Because patients entered the study consecutively, 
block randomization was not possible. At randomiza-
tion, —25% of the patients in each group used conven-
tional treatment with two daily injections of mixed 
insulin. The others were on a multiple daily injection 
regimen. Table 2 shows the baseline features of the pa-
tients at randomization, and no significant differences 
existed between the groups. 
We selected a sample size of n = 2 x 20 to have 
sufficient power of the test for detecting a difference in 
mean blood glucose of 0.6 m M between the two groups 
(a-error <0.05 and ß-error <0.2 in a 2-tailed test). Fifty 
patients entered the study. Four patients from the ex-
perimental group were excluded according to the cri-
teria (2 patients removed the microchip and 2 patients 
developed acute infectious disease). To avoid imbal-
ance between the two groups, four patients from the 
control groups were excluded randomly. 
Each patient was examined over a 32-day period. The 
basic educational program, i.e., practical advice in 
SMBG, diet, and exercise (swimming, hiking) under 
homelike conditions, was identical in both groups. The 
insulin-dose adjustment in the control group was sup-
ported by the educational team only, whereas the ex-
perimental group exclusively received support from the 
learning memory system. The experimental group re-
ceived a 1-h technical instruction course on how to use 
the learning memory system. Data input of one learning 
and one planning phase required ~ 2 min. The experi-
mental group did not participate in the daily consulta-
tions with the educational team, whereas the control 
group did (15 min - day" 1 • patient - 1 ) . The experimental 
group had the opportunity to discuss every problem, 
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except insulin-dose adjustments, with the physicians 
and nurses on the team. They had to determine their 
insulin dosage by themselves, supported only by the 
learning memory system. The control group patients 
were instucted according to the algorithms of Skyler et 
al. (14,15). Düring the study, all patients in both groups 
were treated with multiple daily injections; i.e., one 
injection of short-acting insulin with the main meals and 
long-acting insulin (NPH) in the morning, evening, or 
at bedtime. The patients were told to measure blood 
glucose at least four times a day before breakfast, lunch, 
dinner, and at bedtime. 
Daily blood glucose monitoring was peformed by all 
patients with commercial solid-phase reagent strips 
(Haemogluco Test 2 0 - 8 0 0 , Boehringer Mannheim, 
Mannheim, Germany) referenced two times a day by 
laboratory staff with measurements by glucose oxidase 
method (23). HbA! was determined at the beginning 
and end of treatment by high-performance liquid chro-
matography (5.4-7.6%, between-run SD 0.07%, co-
efficient of Variation 1%; 24). Body mass index was re-
corded at the beginning and end of the treatment. M 
value (25) and mean amplitude of glycemic excursions 
(MAGE) (26) were calculated by an evaluation program 
(27,28), and mean blood glucose and hypoglycemic fre-
quency were determined on the basis of SMBG in the 
first (first 14 days) and second (last 14 days) phases. The 
hypoglycemic frequency is described as the number of 
blood glucose values <3.3 m M per total number of 
blood glucose values during the first and second phases. 
In the case of low blood glucose (<3.3 mM), only one 
measurement is counted within an interval of ± 2 h. 
Statistical analysis. Data are means ± SD. Significant 
differences were determined between the two groups by 
unpaired ( test and within each group with Student's 
paired t test. Because normal distribution was not as-
sumed in hypoglycemic frequency, the U test was ap-
plied. 
TABLE 3 
Parameters of metabolic control, hypoglycemic frequency, 
insulin requirements, and frequency of self-monitoring at 
baseline and at end in experimental and control groups 
Experimental Control 
Metabolic control 
Baseline HbA, (%) 9.8 ± 1 . 6 9.9 ± 1.6 
End HbA t (%) 9.0 ± 1 . 2 * 9.2 ± 1 . 2 * 
Mean blood glucose (mM)t 8.2 ± 1.8 8.5 ± 1.8 
Mean blood glucose (mM)* 8.4 ± 1.4§ 9.2 ± 2.0|| 
Day-to-day Standard deviation 
(mM)t 2.8 ± 0.9 2.9 ± 0.8 
Day-to-day Standard deviation 
(mM)* 2.6 ± 0.81 2.8 ± 0.9 
M value* 22.3 ± 11.1§ 28.7 ± 17.9 
Mean amplitude of glycemic 
excursions (mM)* 7.1 ± 1.411 8.1 ± 2.0 
Proportion of blood glucose 
>11.1 mM(%)t 17.2 ± 12.5 22.5 ± 1 5 . 2 
Proportion of blood glucose 
>11.1mM(%)* 1 6 . 8 ± 0 . 7 § 28.0 ± 1 5 . 1 
Hypoglycemia 
Proportion of blood glucose 
<3.3mM(%)t 3.3 3.7 
Proportion of blood glucose 
<3.3mM(%)* 1.7** 2.3 
Insulin requirement 
Baseline insulin dose/body 
weight (U/kg) 0.63 ± 0.14 0.65 ± 0.13 
End insulin dose/body weight 
(U/kg) 0.57 ± 0 . 1 5 * * 0.64 ± 0.20 
Baseline body mass index 
(kg/mJ) 23.7 ± 3.9 22.7 ± 2.1 
End body mass index (kg/m2) 23.4 ± 3.4 22.4 ± 1.9 
Self-monitoring of blood glucose 
Frequency (day') 5.5 ± 0.8 5.7 ± 0.9 
Values are means ± SD. Phase 1, first 14 days; phase 2, last 14 days. 
*P < 0.001, ||P < 0.01, **P < 0.05, vs. phase 1. 
tPhase 1. 
*Phase 2. 
§P < 0.01, 11P < 0.05, vs. control group. 
RESULTS 
The baseline HbA, levels of the experimental and con-
trol groups did not differ significantly (Table 3). A re-
duction (P < 0.001) in HbA, was observed after the 
32-day treatment period in each group. Mean blood 
glucose of the first 14 days was not different (experi-
mental vs. control, 8.2 vs. 8.5 mM), and the hypogly-
cemic frequency (3.3 vs. 3.7%) was comparable. 
Comparing the first with the second phase, a reduc-
tion (P < 0.05) of the hypoglycemic frequency from 3.3 
to 1.7% was observed in the experimental group, 
whereas the mean blood glucose remained unchanged. 
In the control group, the hypoglycemic frequency de-
creased from 3.7 to 2.3% but at the cost of an increase 
(P < 0.01) of mean blood glucose in the second phase. 
M value (P < 0.01) and M A G E (P < 0.05) were lower 
in the experimental group during the second phase. Se-
vere hypoglycemia with neurological Symptoms or ke-
toacidosis was not observed in any group. 
The insulin requirements per body weight were not 
significantly different at randomization (0.63 vs. 0.65 
U/kg). The insulin requirements decreased (P < 0.01) 
in the experimental group (0.57 U/kg) and remained 
unchanged in the control group (0.64 U/kg). There was 
no significant difference in body mass index at random-
ization or during treatment in both groups. 
The differences between the dose injected by the pa-
tient and the mean of the dosage interval recommended 
by the system followed a distribution with a Standard 
deviation of 0.8 U regulär insulin/injection (0.1 U N P H / 
injection) during the first phase and 0.5 U regulär in-
sulin/injection (0.1 U NPH/injection) during the second 
phase of the study. Because the width of the suggested 
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dosage interval is ±1 U of insulin (i.e., 2 U), most re-
corded dosages are found to be within this interval. 
The parameters of the glucose-insulin model were up-
dated every week during the study and tested for validity 
in a model-fit test by the means of F statistics (29). The 
coefficient of correlation (r) was transformed into an F 
distributed test parameter (see Appendix 2). If this test 
Parameter was 15 (P < 0.01) in the Validation test, the 
adapted model parameters were introduced into the 
continuing feedback process. In 18 of 21 patients, 
model Validation was significant at P < 0.01. 
CONCLUSIONS 
This study compared the safety and metabolic control 
of two training programs for the adjustment of insulin 
dosages. Parameters of glycemic control, i.e., mean 
blood glucose, M value, M A G E , and hypoglycemic fre-
quency, of the group supported by the learning memory 
system were of at least equal quality to the group ad-
vised by the educational team. The duration of a study 
comparing human decision support with that of a Com-
puter is limited by the necessity of providing continuous 
support by diabetes educators. Although we are aware 
of the short-term nature of this study, we conclude that 
patients may receive support in adjusting their insulin 
dose by means of such a system at home where there 
is no education team. For many patients who were given 
their basic education in a hospital or in an education 
center, it is difficult to apply their acquired knowledge 
under the conditions of everyday life. The learning 
memory system may be a representative teacher in such 
situations but should not take the place of any basic 
educational program or consultations with the doctor. 
The internal data processing of the learning memory 
system is based on mathematical modeling of the 
glucose response, which depends on insulin, carbohy-
drate intake, physical activity, and time. Glucose meta-
bolic models are used in the physiological sciences 
(13,30,31) to quantitatively describe internal inacces-
sible metabolic parameters and to predict glucose re-
sponses in a certain individual. A glucose model may 
be inverted for clinical application such that it predicts 
an insulin dose to aim at a defined near-normoglycemic 
target. Some authors designed models for closed-loop 
infusion Systems, whereas this study describes the ap-
plication of a glucose model in intensified insulin ther-
apy (32-36). With SMBG as a data base, the model may 
also identify a valid parametric description of a patient's 
metabolic reactions and may improve the control of his/ 
her blood glucose in a feedback process, Because most 
models are based on data from glucose tolerance tests 
or homeostatic measurements in clamp technique, it has 
not been demonstrated previously that a valid model 
identification based on SMBG is possible. This means 
that records in diabetes self-management contain 
enough information to perform valid mathematical 
modeling. 
The model can be used to estimate the supplemental 
insulin that is necessary to compensate the actual blood 
glucose, extra carbohydrates, and physical exercise in 
the individual patient. The learning memory System can 
be used to determine the supplemental requirements of 
insulin in special situations. Thus, it may be a helpful 
tool for the patient when planning meals and exercise 
in advance. 
Several algorithms have been developed to control 
blood glucose, many of them coded for Computer ap-
plication (1-9,14,15,37,38). The idea of the learning 
memory concept is to combine the Computer data pro-
cessing with the human skills of decision making. The 
learning memory system condenses the information of 
several stored data and prepares the final patient's de-
cision on how to adjust the insulin dose. Patients remain 
active and self-reliant in this program. In the planning-
learning concept, patients may learn from the didactic 
structure of the stored information to distinguish be-
tween prospective and retrospective dose adjustments. 
A self-organizing mutual learning and training process 
between the patient and the System may be interpreted 
as cooperative learning (39). Thus, the System is not an 
alternative technical Controller of blood glucose that re-
places the patient, but more a catalyzer of the learning 
process on how to administer insulin. 
Physicians and patients do not accept Computer sup-
port in general. Therefore, psychosocial aspects, knowl-
edge about diabetes self-management, and the doctor's 
and patient's technological interest should be consid-
ered carefully before such a system is applied. 
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APPENDIX 1: CONTROL ALGORITHMS 
Insulin (INS)-dose adjustments are described by an INS 
Controller on a day-to-day basis. The difference in INS 
dose on 2 successive days is a function of the difference 
between the actual blood glucose (BG) and the refer-
ence input (Rl; eq. 1). The product of the three gain 
factors, jXj, modifies the insulin response on the basis of 
{ n ) preceding blood glucose values. 
AINS = K,(BG - Rl) n M-i 
i=i 
K, = const(1/mM) (1) 
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The quality criterion (e) defines quantitatively to which 
degree BG values reach the near-normoglycemic target 
(Eq. 2). Comparable with the definition of the M value, 
Eq. 2 expresses the asymmetric valuation of hypo- and 
hyperglycemic values. 
= K2 X 
K, = const 
i ( B G { t ) \ 
(2) 
The actual gain factors JXJ in eq. 1 are functions of the 
quality criterion e. The nonlinear gain factor (Eq. 3) |XT 
describes the different insulin responses to hypo- or hy-
perglycemic inputs, respectively. The response to hypo-
glycemia is amplified (ix, >1), whereas it is damped 
(|x, <1) as a reaction to hyperglycemia. 
= 1 + € 
x [K3(e
Kl ,BC-R" 
- const 
+ ki - D 
(3) 
The artifact damping factor |x2 represents a differential 
control element (Eq. 4). A significant difference in two 
successive blood glucose values results in a diminished 
control action. 
= p-K4[BG{M-BGU-l)|-
K4 = const(1 /mM
2) (4) 
The stability gain factor jx3 is proportional to the quality 
criterion e (Eq. 5). In periods of good control, the sta-
bility factor functions as a damping factor to maintain 
stability. 
M-3 = K5 • e 
K5 = const (5) 
The Rl depends on the threshold for symptomatic hypo-
glycemia (H; Eq. 6). BG values are marked by the pa-
tient in the case of symptomatic hypoglycemia. All BG 
values >H have a Statistical probability of <0.20 of 
being marked. 
Rl = Kb + 0.5(H - K6)[sign(H - Kb) + 1] 
Kb = const(mM) (6) 
The system wams if hypo- or hyperglycemia are ex-
pected on the basis of previous calculations. The system 
also wams if insufficient BG decline is observed after 
repeated increases of insulin dosages (16). 
APPENDIX 2: MODEL 
The Statistical model is based on the method of multiple 
correlation. Thus, it has noncompartmental structure 
and describes the process by the vector equation (vu 
date; v2, actual blood glucose; v3, carbohydrate content; 
v 4, physical activity; v 5, basal insulin [NPH]; v 6, regulär 
insulin; y, resulting blood glucose after 4 - 6 h) 
y ( j ) = v(/)Tc 
1 < / < n 
where n is the number of observations, with the char-
acteristic vector 
v(jV = [1v,(/) . . . vp(/)] (8) 
and the parameter vector 
c = |c0c, . . . c p]
T (9) 
The initial parameter (p) vector has been defined on the 
basis of data from literature (18,19). The modeling was 
performed once a week on the basis of the data that 
have been recorded during the previous 3 wk. Each new 
parameter vector is validated by a model-fit test by 
means of F statistics. Validation of the model is per-
formed by the transformation of the coefficient of cor-
relation (r) into an F distributed test parameter (Eq. 10). 
If this test parameter is >15 (P < 0.01), the process 
identification is assumed to be valid. 
F = 
r 2 ( n - p - 1) 
(1 - r>)p 
(10) 
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